Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer’s disease pathology
Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ 42 ) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ 42 /Aβ 40 and p-tau181/Aβ 42 ) for identifying AD pathology (Aβ-PET visual read) across a memory clinic ( n = 129), a primary care ( n = 220) and a research cohort ( n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ 42 (83–92%) had comparable accuracies to CSF (88–90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90–97%) remained comparable to CSF (91%) in the clinical cohorts (all P adj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ 42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.
Authors
- Lyduine Eisa Collij (ORCID: https://orcid.org/0000-0001-6263-1762)
- Nicholas James Ashton (ORCID: https://orcid.org/0000-0002-3579-8804)
- Sebastian Palmqvist (ORCID: https://orcid.org/0000-0002-9267-1930)
- Erik Stomrud (ORCID: https://orcid.org/0000-0002-0841-5580)
- Pontus Tideman (ORCID: https://orcid.org/0000-0002-9620-7115)
- Olof T. Strandberg
- Ruben A Smith (ORCID: https://orcid.org/0000-0001-7147-0112)
- Niklas Mattsson (ORCID: https://orcid.org/0000-0002-8885-7724)
- Oskar Hansson (ORCID: https://orcid.org/0000-0001-8467-7286)
- Gemma Salvadó (ORCID: https://orcid.org/0000-0002-5210-9230)
- Henrik Zetterberg (ORCID: https://orcid.org/0000-0003-3930-4354)
- Shorena Janelidze (ORCID: https://orcid.org/0000-0003-2869-8378)
- Noëlle Warmenhoven (ORCID: https://orcid.org/0009-0003-0557-5102)
- Michael Walter Weiner (ORCID: https://orcid.org/0000-0002-0144-1954)
- Alzheimer’s Disease Neuroimaging Initiative
- Alexa Pichet Binette
Institutions
- University of Wisconsin–Madison (US)
- University of California, San Francisco (US)
- Lund University (SE)
- Sahlgrenska University Hospital (SE)
- Pasqual Maragall Foundation (ES)
- Amsterdam Neuroscience (NL)
- UK Dementia Research Institute (GB)
- Institut Universitaire de Gériatrie de Montréal (CA)
- Barcelonaβeta Brain Research Center (ES)
- Skåne University Hospital (SE)
- Banner Sun Health Research Institute (US)
- Hospital del Mar Research Institute (ES)
- Northern California Institute for Research and Education (US)
- Banner Alzheimer’s Institute (US)
- UCL Queen Square Institute of Neurology (GB)
- University College London (GB)
- Université de Montréal (CA)
- University of Gothenburg (SE)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Nature Aging
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1038/s43587-026-01259-z
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Michael J. Fox Foundation for Parkinson's Research
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Roche
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- Cure Alzheimer's Fund
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Australian Government
- GHR Foundation
- Lunds Universitet
- Eisai
- Vetenskapsrådet
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Skånes universitetssjukhus
- Servier
- H. Lundbeck A/S
- IXICO
- Stiftelsen Bundy Academy
- National Institutes of Health
- Genentech
- Parkinsonfonden
- Canadian Institutes of Health Research
- Janssen Alzheimer Immunotherapy Research And Development